Download Report Global Proto-Oncogene Market and Clinical Pipeline Insight 2024

“Global Proto Oncogene Market and Clinical Pipeline Insight 2024” report gives comprehensive insight on ongoing clinical and non-clinical parameters involved in the development of global proto oncogene market in recent years. Currently there are 19 proto oncogene inhibitors drugs commercially available in the market and 166 are in clinical pipeline in various developmental phases.

“Global Proto Oncogene Market and Clinical Pipeline Insight 2024” report highlights:

* Oncogenes as Therapeutic Targets for Treatment
* Market Analysis of Proto Oncogene Therapeutic Drugs
* Dosage and Price Analysis of Drugs
* Patent and Approval Year Insight
* Proto Oncogene Inhibitors Clinical Pipeline by Company, Indication and Phase
* Marketed Proto Oncogene Inhibitors Clinical Insight by Company and Indication

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-proto-oncogene-market-and-clinical-pipeline-insight-2024.php

Table of Contents

1. Introduction to Proto Oncogenes
1.1 Overview
1.2 Discovery of Transmissible Cancer Gene
1.3 Products of Oncogenes

2. Activation of Proto Oncogene to Oncogenes
2.1 From Proto Oncogenes to Oncogenes
2.1.1 Gene Amplification
2.1.2 Chromosomal Translocation
2.1.3 Mutations
2.2 Hallmarks of Cancer

3. Oncogenes as Therapeutic Targets for Treatment
3.1 ERBB2 as a Target for Breast Cancer Therapy
3.2 EGFR as a Target for Colorectal Cancer Therapy
3.3 VEGF as a Target for Non-Small Cell Lung Cancer
3.4 PDGFR as a Target for Renal Cell Carcinoma

4. Prognostic and Predictive Role of Oncogenes
4.1 HER2
4.2 BRAF V600E
4.3 BCL-2
4.4 SRC

5. Market Analysis of Proto Oncogene Therapeutic Drugs
5.1 Axitinib (Inlyta)
5.2 Ponatinib (Iclusig)
5.3 Imatinib (Gleevec)
5.4 Sunitinib (Sutent)
5.5 Pazopanib (Votrient)
5.6 Dabrafenib (Tafinlar)
5.7 Vandetanib (Caprelsa)
5.8 Vemurafenib (Zelboraf)
5.9 Cabozantinib (Cabometyx and Cometriq)
5.10 Sorafenib (Nexavar)

6. Market Introduction of Proto Oncogenes
6.1 Overview
6.2 Global Sales of Proto-Oncogene Drugs
6.3 Global Proto Oncogene Protein Inhibitors Pipeline Overview

7. Global Proto Oncogene Market Dynamics
7.1 Favorable Market Parameters
7.2 Commercialization Challenges

8. Future Perspective of Proto Oncogene Market

9. Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
9.8 Preregistration
9.9 Registered

10. Marketed Global Proto-Oncogene Protein Inhibitors Clinical Insight by Company and Indication
10.1 Axitinib (Inlyta)
10.2 Ponatinib (Iclusig)
10.3 Imatinib (Gleevec, Glivec and Ruvise)
10.4 Lenvatinib (Kisplyx and Lenvima)
10.5 Sunitinib (Sutent)
10.6 Pazopanib (Votrient)
10.7 Dabrafenib (Tafinlar)
10.8 Vandetanib (Caprelsa, Zactima and Zictifa)
10.9 Vemurafenib (Zelboraf)
10.10 Cabozantinib (Cabometyx and Cometriq)
10.11 Nilotinib (Tasigna)
10.12 Regorafenib (Stivarga)
10.13 Dasatinib (Sprycel)
10.14 Sorafenib (Nexavar)
10.15 Crizotinib (Xalkori)
10.16 Apatinib
10.17 Omacetaxine Mepesuccinate (Synribo)
10.18 Imatinib - Pharm-Sintez (Imatib)
10.19 Phaleria Macrocarpa extract (Phalecarps)

11. Competitive Landscape
11.1 ARIAD Pharmaceuticals
11.2 AstraZeneca
11.3 Bayer Healthcare
11.4 Bristol-Myers Squibb
11.5 ChemGenex Pharmaceuticals
11.6 Dexa Medica
11.7 Eisai Pharmaceuticals
11.8 Exelixis
11.9 GlaxoSmithKline
11.10 Novartis
11.11 Onyx Pharmaceuticals
11.12 Plexxikon
11.13 Pfizer

Figure 1-1: Historical Development of Oncogenes in Various Cancer Cell Lines
Figure 1-2: Organization of the Proto Oncogene Products
Figure 2-1: Activation Methods of Oncogenes from Proto Oncogenes
Figure 2-2: Gene Amplification Step in the Conversion of Proto Oncogenes to Oncogenes
Figure 2-3: Chromosomal Translocation for the Activation Oncogene from Proto Oncogene
Figure 2-4: Classification of the Hallmarks of Cancer
Figure 3-1: Role of VEGF as a Target to Non-Small Cell Lung Cancer
Figure 3-2: PDGFR Target for the Treatment of Renal Cell Carcinoma
Figure 5-1: Axitinib- Patent Approval and Expiration Year in US
Figure 5-2: Axitinib- Patent Approval and Expiration Year in Europe
Figure 5-3: Axitinib Dosage Analysis (mg/Day)
Figure 5-4: Available Concentrations of Axitinib Oral Tablet (mg)
Figure 5-5: Inlyta- Price Analysis by Concentration (US$/Unit), 2018
Figure 5-6: Axitinib Price Analysis US$/Packet), 2018
Figure 5-7: Axitinib Treatment Cost (US$/Cycle), 2017
Figure 5-8: Ponatinib- Patent Approval Year and Expiration Year in US
Figure 5-9: Ponatinib- Patent Approval Year and Expiration Year in Europe
Figure 5-10: Iclusig Dosage Analysis (mg/Day)
Figure 5-11: Available Concentrations of Iclusig Oral Tablet Drug, mg
Figure 5-12: Iclusig- Price Analysis (US$), 2017
Figure 5-13: Imatinib- Patent Approval Year and Patent Expiration Year in US
Figure 5-14: Imatinib- Patent Approval Year and Patent Expiration Year in Europe
Figure 5-15: Imatinib Price Analysis by Concentration (US$/Unit), 2017
Figure 5-16: Imatinib Price Analysis by Concentration (US$/Packet), 2017
Figure 5-17: Sunitinib- Patent Approval Year and Expiration Year in US
Figure 5-18: Sunitinib- Patent Approval Year and Expiration Year in Europe
Figure 5-19: Available Concentrations of Sunitinib Drug, mg
Figure 5-20: Sutent Capsule Price by Concentration (US$/Unit), 2017
Figure 5-21: Sunitinib- Price Analysis by Concentration (US$/Packet), 2017
Figure 5-22: Pazopanib- Patent Approval Year and Patent Expiration Year in US
Figure 5-23: Pazopanib- Patent Approval Year and Patent Expiration Year in Europe
Figure 5-24: Pazopanib Dosage Analysis (mg/Day)
Figure 5-25: Pazopanib Price Analysis by Quantity (US$), 2017
Figure 5-26: Dabrafenib- Patent Approval and Expiration Year in US
Figure 5-27: Dabrafenib- Patent Approval and Expiration Year in Europe
Figure 5-28: Dabrafenib Dosage Analysis (mg/Day)
Figure 5-29: Available Concentration of Dabrafenib Drug, mg
Figure 5-30: Dabrafenib Price Analysis by Concentration (US$/Unit), 2017
Figure 5-31: Tafinlar Capsule Average Price Analysis by Concentration (US$/120 Capsules), 2017
Figure 5-32: Vandetanib- Patent Approval and Expiration Year in US
Figure 5-33: Vandetanib- Patent Approval and Expiration Year in Europe
Figure 5-34: Vandetanib Dosage Analysis (mg/Day)
Figure 5-35: Available Concentrations of Vandetanib Drug, mg
Figure 5-36: Vandetanib Price Analysis (US$/Unit), 2017
Figure 5-37: Vandetanib- Drug Cost (US$) in Concentration of 100 mg and 300 mg for 30 Tablets, 2017
Figure 5-38: Vemurafenib- Patent Approval Year and Expiration Year in US and Europe
Figure 5-39: Vemurafenib- Patent Approval Year and Expiration Year in Europe
Figure 5-40: Vemurafenib Dosage Analysis (mg/Day)
Figure 5-41: Vemurafenib- Market Cost of Drug (US$) for 112 Tablets and Per Unit Cost, 2017
Figure 5-42: Cabozantinib- Patent Approval Year and Expiration Year in US
Figure 5-43: Cabozantinib- Patent Approval Year and Expiration Year in Europe
Figure 5-44: Cabozantinib Dosage Analysis (mg/Day)
Figure 5-45: Available Concentrations of Cabozantinib Oral Tablet, mg
Figure 5-46: Available Drug Concentrations of Cometriq Oral Capsule, mg
Figure 5-47: Cabozantinib- Drug Cost of 20mg Concentration (US$) for 30 Tablets and Per Unit Dose, 2017
Figure 5-48: Cost of Cometriq Capsules for the Supply of 50 Capsules of Different Concentrations, (US$)
Figure 5-49: Sorafenib- Patent Approval Year and Expiration Year in US
Figure 5-50: Sorafenib- Patent Approval Year and Expiration Year in Europe
Figure 5-51: Sorafenib- Drug Cost for 120 Tablets and Per Unit Dose (US$), 2017
Figure 6-1: Global- Axitinib Drug Sales (US$ Million), 2015 and 2016
Figure 6-2: Iclusig andndash; Sales (US$ Million), 2015
Figure 6-3: Iclusig andndash; Sales (US$), 2016 and 2017
Figure 6-4: Global- Sales Revenue of Sunitinib Drug (US$ Billion), 2015 and 2016
Figure 6-5: Global- Sales of Pazopanib Drug (US$ Million), 2015 and 2016
Figure 6-6: Global- Sales Revenue of Vemurafenib Drug (US$ Million), 2015 and 2016
Figure 6-7: Global- Sales of Imatinib (US$ Billion), 2014-2017
Figure 6-8: Global Sales of Dabrafenib Drug (US$ Million), 2015 and 2016
Figure 6-9: Global Sales Revenue of Sorafenib Drug (US$ Million), 2014-2016
Figure 6-10: Cabozantinib (Cabometyx and Cometriq) andndash; Sales (US$ Million), 2016 and 2017*
Figure 6-11: Cabometyx and Cometriq andndash; Sales (US$ Million), 2016 and 2017*
Figure 6-12: Global Proto Oncogene Protein Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
Figure 6-13: Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
Figure 7-1: Favorable Factors which Promote the Market Growth of Proto Oncogenes
Figure 7-2: Challenges to the Market Growth of Proto Oncogenes
Figure 8-1: Frontiers for the Inhibition of Cancer Development by Active Oncogenes






Table 3-1: Possible Ways to Overcome ErBb2 Mediated Chemoresistance
Table 3-2: Components of EGFR Signaling Pathway Important in Colorectal Cancer
Table 4-1: Role of Cancer Oncogene as Predictive and Prognostic Biomarker
Table 5-1: Imatinib Dosage for Various Indications (mg/Day and mg/m2/Day)
Table 5-2: Cost Effective Analysis of Imatinib Drug
Table 5-3: Clinical Efficacy Results of Sunitinib Drug in Cancer Treatment
Table 5-4: Clinical Efficacy Results of Pazopanib Drug in Cancer Treatment
Table 5-5: Clinical Effective Analysis of Dabrafenib Drug
Table 5-6: Clinical Effective Analysis of Vandetanib Drug
Table 5-7: Clinical Efficacy of Vemurafenib Drug in Cancer Treatment

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.